SystImmune

Executive Summary

SystImmune is a private biopharmaceutical company headquartered in Redmond, Washington, focused on developing next-generation bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for oncology. Founded in 2018, the company's mission is to create biologics that directly attack tumors while simultaneously activating the immune system to enhance anti-tumor responses. By leveraging proprietary platforms for multi-specific antibody engineering and ADC technology, SystImmune aims to address key limitations of conventional cancer therapies, including drug resistance and immune evasion. The company operates in the increasingly competitive yet high-potential ADC and bispecific antibody space, which has attracted significant interest from large pharma and investors. Although SystImmune is still in the early stages of development with no disclosed pipeline or clinical-stage assets, its focus on innovative mechanisms positions it as a potential player in precision oncology. The company's private status limits public financial disclosures, but its technology platform and therapeutic strategy align with current industry trends toward combination therapies and targeted payload delivery.

Upcoming Catalysts (preview)

• Q3 2026Lead program IND filing for first-in-class bispecific ADC60% success
• Q4 2026Publication of preclinical data in peer-reviewed journal80% success
• Q3 2026Strategic partnership or licensing deal for platform technology40% success